Interferon alfa-2a: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag={{RB}}
|genericName=Interferon alfa-2a
|aOrAn=a
|aOrAn=a
|drugClass=antiviral
|indicationType=treatment
|indicationType=treatment
|hasBlackBoxWarning=Yes
|indication=RECURRENT VIRAL INFECTIONS
|adverseReactions=<!--Black Box Warning-->
|adverseReactions=black stools, chills, cough, fever, irritability
 
 
 
<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content
 


<!--Adult Indications and Dosage-->
<!--Adult Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
|fdaLIADAdult=====Indications====
 
* RECURRENT VIRAL INFECTIONS
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====


There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
====Directions====
Take 15 minutes before meals.
Adults and children 12 years and older    20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed=====Indications====
RECURRENT VIRAL INFECTIONS


* Dosing Information
====Directions====
 
Children  between 12 years and 6 years of age    10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow.
:* Dosage
Children under 6 years    5 drops twice a day in a glass of water.
 
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
|contraindications=* Condition1
|contraindications=


<!--Warnings-->
<!--Warnings-->
|warnings=* Description
|warnings=* Stop use and ask doctor if symptoms worsen or persist more than 3 days
 
====Precautions====
 
* Description


<!--Adverse Reactions-->
<!--Adverse Reactions-->
Line 189: Line 120:


<!--Postmarketing Experience-->
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=black stools, chills, cough, fever, irritability
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
|drugInteractions=* Drug
:* Description
:* Description
Line 266: Line 143:
|administration=* Oral
|administration=* Oral


* Intravenous
 
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
Line 275: Line 151:


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|overdose=There is limited information regarding <i>Overdose</i> of {{PAGENAME}} in the drug label.
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.


<!--Pharmacology-->
<!--Pharmacology-->
Line 296: Line 160:


<!--Structure-->
<!--Structure-->
|structure=*  
|structure=* ACTIVE INGREDIENT
INTERFERON ALFA-2A      4C
INACTIVE INGREDIENT
Ethyl Alcohol 30%
 


: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
Line 314: Line 181:
<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|packLabel=PRINCIPAL DISPLAY PANEL
: [[File:Inter PDP.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
====Ingredients and Appearance====
: [[File:Inter I n A.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
 
<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


Line 321: Line 195:


<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
|brandNames=* GUNA-INF ALPHA®<ref>{{Cite web | title = Interferon alfa-2a | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f96495b5-1ffe-432c-adcf-b2db9cfd1405}}</ref>


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
|lookAlike=There is limited information regarding the look alike drug names.
 
<!--Drug Shortage Status-->
|drugShortage=
|drugShortage=
}}
}}

Revision as of 19:52, 28 April 2015

Interferon alfa-2a
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Interferon alfa-2a is a antiviral that is FDA approved for the treatment of RECURRENT VIRAL INFECTIONS. Common adverse reactions include black stools, chills, cough, fever, irritability.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

  • RECURRENT VIRAL INFECTIONS

Directions

Take 15 minutes before meals. Adults and children 12 years and older 20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Interferon alfa-2a in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Interferon alfa-2a in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Indications

RECURRENT VIRAL INFECTIONS

Directions

Children between 12 years and 6 years of age 10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children under 6 years 5 drops twice a day in a glass of water.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Interferon alfa-2a in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Interferon alfa-2a in pediatric patients.

Contraindications

There is limited information regarding Interferon alfa-2a Contraindications in the drug label.

Warnings

  • Stop use and ask doctor if symptoms worsen or persist more than 3 days

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Interferon alfa-2a in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

black stools, chills, cough, fever, irritability

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Interferon alfa-2a in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Interferon alfa-2a during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Interferon alfa-2a with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Interferon alfa-2a with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Interferon alfa-2a with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Interferon alfa-2a with respect to specific gender populations.

Race

There is no FDA guidance on the use of Interferon alfa-2a with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Interferon alfa-2a in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Interferon alfa-2a in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Interferon alfa-2a in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Interferon alfa-2a in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral

Monitoring

There is limited information regarding Monitoring of Interferon alfa-2a in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Interferon alfa-2a in the drug label.

Overdosage

There is limited information regarding Overdose of Interferon alfa-2a in the drug label.

Pharmacology

There is limited information regarding Interferon alfa-2a Pharmacology in the drug label.

Mechanism of Action

Structure

  • ACTIVE INGREDIENT

INTERFERON ALFA-2A 4C INACTIVE INGREDIENT Ethyl Alcohol 30%

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Interferon alfa-2a in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Interferon alfa-2a in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Interferon alfa-2a in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Interferon alfa-2a in the drug label.

How Supplied

Storage

There is limited information regarding Interferon alfa-2a Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Interferon alfa-2a |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

PRINCIPAL DISPLAY PANEL

This image is provided by the National Library of Medicine.

Ingredients and Appearance

This image is provided by the National Library of Medicine.

{{#ask: Label Page::Interferon alfa-2a |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Interferon alfa-2a in the drug label.

Precautions with Alcohol

  • Alcohol-Interferon alfa-2a interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • GUNA-INF ALPHA®[1]

Look-Alike Drug Names

There is limited information regarding the look alike drug names.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "Interferon alfa-2a".

{{#subobject: 

 |Page Name=Interferon alfa-2a
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject: 

 |Label Page=Interferon alfa-2a
 |Label Name=Interferon alfa-2a11.png

}}

{{#subobject: 

 |Label Page=Interferon alfa-2a
 |Label Name=Interferon alfa-2a11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Interferon_alfa-2a&oldid=1092789"